Patents Assigned to Immunex
  • Publication number: 20060100151
    Abstract: Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
    Type: Application
    Filed: December 20, 2005
    Publication date: May 11, 2006
    Applicant: Immunex Corporation
    Inventor: Anthony Troutt
  • Patent number: 7041282
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using fit3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: May 9, 2006
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, M. Patricia Beckmann
  • Patent number: 7041782
    Abstract: The invention is directed to purified and isolated novel ss3939 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: May 9, 2006
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Patent number: 7037675
    Abstract: The invention is directed to purified and isolated SIGIRR polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: May 2, 2006
    Assignee: Immunex Corporation
    Inventor: John Ernest Sims
  • Patent number: 7033783
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: April 25, 2006
    Assignee: Immunex Corp.
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Publication number: 20060078564
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: December 9, 2005
    Publication date: April 13, 2006
    Applicant: Immunex Corporation
    Inventor: David Cosman
  • Patent number: 7014853
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: March 21, 2006
    Assignee: Immunex Corporation
    Inventor: David J. Cosman
  • Patent number: 7008624
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: March 7, 2006
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Patent number: 7005412
    Abstract: Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor IL-1 and/or TNF.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: February 28, 2006
    Assignee: Immunex Corporation
    Inventor: Anthony B. Troutt
  • Patent number: 7001752
    Abstract: The inventions is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acid encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: February 21, 2006
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, G. Duke Virca, Unja Martin, Dirk M. Anderson
  • Patent number: 7001599
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: February 21, 2006
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims
  • Patent number: 6994989
    Abstract: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: February 7, 2006
    Assignee: Immunex Corp.
    Inventor: Stewart D. Lyman
  • Publication number: 20060024807
    Abstract: The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 2, 2006
    Applicant: Immunex Corporation
    Inventors: Timothy Bird, G. Virca, Unja Martin, Dirk Anderson
  • Publication number: 20060018892
    Abstract: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.
    Type: Application
    Filed: September 2, 2005
    Publication date: January 26, 2006
    Applicant: Immunex Corporation
    Inventors: Howard Clarke, Robert DuBose, Steven Wiley
  • Publication number: 20060014252
    Abstract: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.
    Type: Application
    Filed: September 14, 2005
    Publication date: January 19, 2006
    Applicant: Immunex Corporation
    Inventor: Stewart Lyman
  • Publication number: 20050281824
    Abstract: The invention relates to the discovery that IMXP-888, a protein with homology to the FGF receptor family, is a proinflammatory cytokine. The invention encompasses therapeutic compositions of IMXP-888 polypeptides and antagonists, methods of use thereof, and screening methods.
    Type: Application
    Filed: July 21, 2005
    Publication date: December 22, 2005
    Applicant: Immunex Corporation
    Inventors: Stewart Chipman, Kenneth Schooley, Teresa Born, Robert DuBose
  • Patent number: 6974681
    Abstract: The invention provides methods and compositions for improved in vitro culture of cells that make use of vanadate. The methods enhance cell survival thereby recovery of the polypeptide of interest produced in the cells is increased relative to cells grown without vanadate.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: December 13, 2005
    Assignee: Immunex Corporation
    Inventor: Jeffrey T McGrew
  • Patent number: 6972327
    Abstract: The invention provides improved methods of regenerating and using affinity chromatography material, in particular Protein A affinity chromatography resins.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: December 6, 2005
    Assignee: Immunex Corporation
    Inventors: Hassan Madani, Robert D. Hershberg
  • Publication number: 20050266421
    Abstract: This invention relates to new members of the human Claudin polypeptide family, to methods of making such polypeptides, and to methods of using them to treat Claudin-associated conditions and to identify agents that alter Claudin polypeptide activities.
    Type: Application
    Filed: October 15, 2004
    Publication date: December 1, 2005
    Applicant: Immunex Corporation
    Inventors: Timothy Bird, Adel Youakim
  • Patent number: 6958387
    Abstract: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.
    Type: Grant
    Filed: March 8, 2002
    Date of Patent: October 25, 2005
    Assignee: Immunex Corporation
    Inventors: Howard R. G. Clarke, Robert F. DuBose, Steven R. Wiley